Immunogenicity and Safety of a Booster Dose of an Investigational Adjuvanted Polyprotein HIV-1 Vaccine in Healthy Adults and Effect of Administration of Chloroquine

Supplemental material

Files in this Data Supplement:

• Supplemental file 1 -

  Fig. S1. (A) Frequency of CD4⁺ T cells expressing IL-2 and at least one other cytokine in response to the F4 fusion protein and (B) geometric mean concentrations for anti-F4 antibodies after administration of the booster doses of the F4/AS01B-adjuvanted HIV type 1 investigational vaccine in the chloroquine and the control groups (ATP immunogenicity cohort). Fig. S2. (A and B) Stimulation index of CD4⁺ CFSE^low T cells stimulated with F4 peptide pools and (C and D) frequency of F4- and TRAP-specific CD4⁺ CFSE^low T cells expressing at least one cytokine following primary and booster doses of the F4/AS01B investigational vaccine in the chloroquine (A and C) and the control (B and D) groups (ATP immunogenicity cohort). Table S1. CD4⁺ T-cell response to the F4/AS01-adjuvanted HIV type 1 vaccine after stimulation with p17, p24, RT, and Nef peptide pools: responder rates (pooled ATP immunogenicity cohort for 10-μg-primed participants).

  PDF, 262K